Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Evi Horn"'
Autor:
Johannes Dietl, J Diessner, Roland Stein, Tanja Stüber, Jörg Wischhusen, Petra Hauck, Claus J. Scholz, Stefan Ebert, Matthias Braun, Matthias Wölfl, Laura Schlahsa, Vincent J. Thiemann, Andreas Rosenwald, Camelia-Maria Monoranu, Achim Wöckel, Michael P. Wustrow, Itsaso Montalbán del Barrio, Sebastian Häusler, Evi Horn
Publikováno v:
Cancer Research. 79:1507-1519
Targeting of tumor immune escape mechanisms holds enormous therapeutic potential. Still, most patients progress under immune checkpoint blockade and some even become hyperprogressors. To investigate how cancer cells respond to activated but ineffecti
Autor:
Roland G, Stein, Stefan, Ebert, Laura, Schlahsa, Claus J, Scholz, Matthias, Braun, Petra, Hauck, Evi, Horn, Camelia-Maria, Monoranu, Vincent J, Thiemann, Michael P, Wustrow, Sebastian F, Häusler, Itsaso, Montalbán Del Barrio, Tanja N, Stüber, Matthias, Wölfl, Johannes, Dietl, Andreas, Rosenwald, Joachim E, Diessner, Achim, Wöckel, Jörg, Wischhusen
Publikováno v:
Cancer research. 79(7)
Targeting of tumor immune escape mechanisms holds enormous therapeutic potential. Still, most patients progress under immune checkpoint blockade and some even become hyperprogressors. To investigate how cancer cells respond to activated but ineffecti
Autor:
Evi Horn, Arnd Honig, Johannes Dietl, Melanie Schmidt, Mathias Krockenberger, Jörg Wischhusen, Tanja Schönhals, Frank Köster, Jörg B. Engel, Sebastian Häusler
Publikováno v:
Archives of Gynecology and Obstetrics. 283:603-610
We analyzed the anti-tumor effect and the mechanism of action of perifosine, an orally active alkylphospholipid AKT inhibitor using in vitro models of human ovarian cancer.Ovarian cancer cells OAW42, PA-1, SKOV3, and A2780 as well as platinum resista
Publikováno v:
Geburtshilfe und Frauenheilkunde. 73
Autor:
Mathias, Krockenberger, Peter, Kranke, Sebastian, Häusler, Jörg Bernhard, Engel, Evi, Horn, Katharina, Nürnberger, Jörg, Wischhusen, Johannes, Dietl, Arnd, Hönig
Publikováno v:
Anticancer research. 32(12)
Ovarian cancer is generally thought of as a cancer with poor prognosis. However, prognostic appraisal of the disease is based on tumor stages, surgical features or sensibility towards platinum-based chemotherapy. There are data that also grant immuno
Autor:
Ahmed Adel Seida, Stefan Heuer, Jenny Strohschein, Itsaso Montalbán del Barrio, Markus Junker, Jörg Wischhusen, Birgitt Fischer, Hermann Kneitz, Monika Ossadnik, Doris Kloor, Sebastian Häusler, Jörg B. Engel, Arnd Honig, Karl-Norbert Klotz, Mathias Krockenberger, Evi Horn, P. Anoop Chandran, Johannes Dietl
Publikováno v:
Cancer immunology, immunotherapy : CII. 60(10)
The ectonucleotidases CD39 and CD73 degrade immune stimulatory ATP to adenosine that inhibits T and NK cell responses via the A(2A) adenosine receptor (ADORA2A). This mechanism is used by regulatory T cells (T(reg)) that are associated with increased
Publikováno v:
Journal of immunological methods. 361(1-2)
Extracellular adenosine exerts powerful paracrine effects on immune cells. Thus, adenosine signaling has to be strictly regulated. This is achieved by its rapid internalization or enzymatic degradation. Consequently, free adenosine is extremely diffi
Autor:
Arnd Honig, J. F. Coy, Mathias Krockenberger, Lorenz Rieger, Johannes Dietl, Evi Horn, Ulrike Kämmerer, Michaela Kapp, M. Sütterlin
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 17(1)
Tumorbiology of ovarian cancer remains unclear. However, it is known that ovarian tumors, especially carcinomas, show elevated expression of glucose membrane transporters for facilitated glucose uptake. It can be assumed that increased glucose uptake
Autor:
J Wischhusen, J Diessner, Roland Stein, Johannes Dietl, Arnd Honig, Sebastian Häusler, Valentin Bruttel, Evi Horn
Publikováno v:
Cell Death & Disease
The antibody trastuzumab (Herceptin) has substantially improved overall survival for patients with aggressive HER2-positive breast cancer. However, about 70% of all treated patients will experience relapse or disease progression. This may be related